| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
1 company
George Kelly Martin last filed a Form 4 in August 2024 for TLSI. George Kelly Martin's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 247,176 shares of TLSI. The TLSI filings lean toward selling, a net 9 shares.
George Kelly Martin has 3 Form 4 filings on record from August 2023 to August 2024, all as TriSalus Life Sciences (TLSI), 2023–2024.
The 3 reported transactions were 2 option or other derivative awards and 1 open-market sale.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $50.
The only open-market sale was 9 shares of TLSI at an average $5.50 on August 28, 2024, about $50. Twelve months later TLSI was up 2%.
Shares as reported in the last Form 4 for each company; the most recent is from August 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 28, 2024 | TLSI Trisalus Life Sciences, Inc. | - | Sell | 9 | $5.50 | $49.50 | - | -13.4% | +2.4% |